![]() Subanalysis by Tanner Stage in Phase 3 Trials in Children and Adolescents with Growth Hormone Deficiency Treated with Lonapegsomatropin Late Breaker: Poster, Saturday, June 17, 1:00 – 2:00 pm (CDT) Prevalence of Comorbidities Among Treated and Untreated Adults with Suspected Growth Hormone Deficiency ![]() ![]() Poster, Thursday, Thursday, June 15, 12:30 - 1:30 pm (CDT) Significantly Improved Annual Height Velocity with Once-Weekly TransCon CNP in Children with Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial Oral presentation, Saturday, June 17, 4:30-4:45 pm (CDT))Ĭlinical and Economic Burden of Postsurgical Chronic Hypoparathyroidism: A U.S. Long-Term Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results from the Open-Label Extension of the PaTHway Phase 3 Trial In addition, Ascendis will host booth #1628, booth #1740, and two product theaters during ENDO 2023. Phase 3 Week 52 data for TransCon ™ PTH in adults with hypoparathyroidism selected for oral presentationĬOPENHAGEN, Denmark, J(GLOBE NEWSWIRE) - Ascendis Pharma A/S (Nasdaq: ASND) today announced it will showcase its latest Endocrinology Rare Disease programs, data, and research in growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome at ENDO 2023, the annual meeting of the Endocrine Society being held June 15-18 in Chicago.Īn oral presentation on Saturday, June 17, will feature Phase 3 Week 52 data for TransCon PTH in adults with hypoparathyroidism, and five additional poster presentations listed in the table below will showcase other Ascendis programs and data. The money – which is the first financial award in a case brought against the pharmacies in a federal court – will be allocated to tackle an opioid crisis in Lake and Trumbull counties, located outside Cleveland.Īttorneys for the counties, who accused the pharmacies of dispensing vast quantities of opioids whilst turning a blind eye to abuse of the drugs – have said they estimate the cost of combatting opioid abuse could run to $3.3 billion.ĬVS, Walmart, and Walgreens have all said they will appeal the ruling, insisting they neither manufactured or marketed opioids, nor distributed them to illegal 'pill mills' and rogue Internet pharmacies that they claim fuelled the epidemic of opioid abuse.- Endocrinology clinical development progress and research i n growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted Meanwhile, three of the largest pharmacy chains in the US – CVS, Walgreens and Walmart – have been ordered to pay $650 million to two Ohio counties in the wake of a jury trial, which found them culpable of fuelling the opioid crisis last November. The settlement would ban Endo from promoting opioids and require it to hand over millions of documents related to its role in the opioid crisis for publication in a public online archive. Separately, the company also agreed in principle a deal with 34 US states to provide $450 million over a period of ten years, to resolve allegations that the company boosted opioid sales using deceptive marketing practices. In a statement, Endo said its plans would result in a "substantial" reduction in debt and would create voluntary trusts funded with $550 million set aside for "certain opioid claims." ![]() The Ireland-domiciled company is struggling under the weight of around $8 billion in debt, and has been hamstrung by costs associated with fighting thousands of suits that accuse it of wrongdoing in its marketing and promotion of painkiller Opana ER (oxymorphone), which was withdrawn from the market five years ago, as well as oxycodone-based products Percocet and Endocet.Įndo's slide into bankruptcy follows in the footsteps of Purdue Pharma – which filed in 2019 but is still negotiating opioid settlement and corporate restructuring terms – as well as Mallinckrodt, which emerged from chapter 11 after agreeing a $1.6 billion settlement earlier this year. Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that includes an offer to settle outstanding lawsuits.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |